Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
News for Inogen Inc (INGN) centers on its activities as a medical technology company focused on respiratory products for homecare use. This page aggregates company press releases, earnings announcements, product launches, and other public updates that Inogen provides to investors, patients, and partners.
Inogen regularly issues quarterly financial results and outlook updates, detailing revenue by sales and rental categories, business-to-business and direct-to-consumer performance, gross margin trends, operating expenses, and non-GAAP measures such as EBITDA and adjusted EBITDA. These releases often highlight factors driving performance, such as demand from domestic and international business-to-business customers and changes in direct-to-consumer and rental revenue.
Product-related news is another key theme. Recent announcements include the launch of the Voxi 5 stationary oxygen concentrator, designed to expand access to oxygen therapy for long-term care patients in the United States, and the introduction of Aurora CPAP masks for patients with obstructive sleep apnea. Such updates illustrate how Inogen is broadening its respiratory care portfolio beyond portable oxygen concentrators into stationary oxygen therapy and sleep-therapy accessories.
Corporate and leadership developments, such as technology and executive appointments, also appear in Inogen’s news flow, offering context on how the company is organizing around digital health, connected devices, and operational execution. Investors and observers can use this news page to follow Inogen’s financial trajectory, portfolio evolution, and strategic priorities in home respiratory and sleep care.
For anyone tracking INGN stock, revisiting this page provides a consolidated view of Inogen’s latest earnings releases, conference call announcements, and product milestones, all drawn from the company’s own public communications.
Inogen (Nasdaq: INGN) appointed Vafa Jamali as an independent director, effective at the Company’s 2026 Annual Meeting or June 15 if earlier. Mr. Jamali brings medical device leadership, including prior roles leading a $3 billion division and overseeing 10,000 team members.
The company entered a cooperation agreement with investor Kent Lake that includes customary standstill and voting provisions; the agreement will be filed on Form 8-K. Evercore, Covington & Burling, and Joele Frank advise the company.
Inogen (Nasdaq: INGN) said CEO Kevin Smith will appear in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 10:15 a.m. ET. A live audio webcast and archived recording will be available on Inogen's investor relations website.
The company also stated it uses its investor relations website as a channel for disclosing material non-public information and to comply with Regulation FD.
Inogen (Nasdaq: INGN) announced inducement equity awards approved under Nasdaq Listing Rule 5635(c)(4) for two new executives joining the company. Jason Richardson will receive 200,000 RSUs (100,000 time-based; 100,000 performance-based, up to 150,000 PSUs if goals are exceeded). Dominic Hulton will receive $200,000 in time-based RSUs, with his start expected on April 1, 2026. Vesting for both grants is generally one-third annually over three years for the time-based RSUs; PSUs vest upon achievement of specified performance goals. Awards are outside the company’s 2023 equity plan but follow similar terms.
Inogen (Nasdaq: INGN) announced leadership changes to support its next growth phase, naming Jason Richardson as CFO effective April 6, 2026, Dominic Hulton as Chief Marketing Officer effective April 1, 2026, and Corey Moritz as VP, U.S. B2B Sales (joined March 9, 2026).
The company said Michael Bourque will step down as CFO and remain as advisor through June 30, 2026. Inogen also reaffirmed its Q1 and full year 2026 financial outlook provided on February 24, 2026.
Inogen (Nasdaq: INGN) announced that CEO Kevin Smith will appear in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 17, 2026 at 3:00 PM ET. A live audio webcast and archived recording will be available via the company investor relations website.
Inogen said it uses its investor relations site for disclosing material non-public information and to comply with Regulation FD.
Inogen (NASDAQ: INGN) reported full year 2025 results and 2026 outlook. Full year revenue was $348.7M, roughly 4% growth, with GAAP net loss of $22.7M and positive adjusted EBITDA of $2.7M. Cash and marketable securities were $120.9M with no debt and a $30M share repurchase authorization.
The company cited international POC sales strength and operational cost reductions, expects Q1 2026 revenue roughly in line with Q1 2025, and full year 2026 revenue guidance of $366M–$373M.
Inogen (Nasdaq: INGN) announced a $30 million share repurchase program authorized by its Board of Directors on February 24, 2026. The program will be financed through cash flow and existing cash reserves and may be suspended or terminated at any time.
The authorization expires on December 31, 2027, or once the $30 million cap is used, whichever occurs first. The company said the buyback reflects confidence in its strategy, progress toward profitability, a debt-free balance sheet, and provides flexibility to support innovation and portfolio expansion.
Inogen (Nasdaq: INGN) announced preliminary, unaudited revenue for Q4 2025 of approximately $82 million (≈2% YoY) and full‑year 2025 revenue of approximately $349 million (≈4% YoY). The company expects to achieve positive Adjusted EBITDA for 2025 and cited strong B2B channel performance offset by timing shifts of several large customer orders into H1 2026. Management highlighted product launches during 2025 including the Voxi 5 stationary oxygen concentrator and Aurora Masks for OSA patients in the U.S. Inogen will release full results and 2026 guidance on a February 24, 2026 earnings call.
Inogen (Nasdaq: INGN) announced the U.S. launch of Aurora CPAP masks for obstructive sleep apnea on January 7, 2026, expanding its respiratory care portfolio into the sleep-therapy market.
Key facts: FDA 510(k) cleared masks offered through certified partners; portfolio includes F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows; product claims universal CPAP compatibility, quiet venting, and simple maintenance. A 30-day AMG trial of 140 patients reported a majority were highly satisfied.
Inogen (NASDAQ: INGN) reported Q3 2025 results on November 5, 2025 with $92.4 million revenue, up 4.0% year-over-year, marking the seventh consecutive quarter of mid-single-digit growth. GAAP net loss was $5.3 million (including $1.8 million of one-time legal and settlement expenses) while adjusted net loss narrowed to $0.5 million and adjusted EBITDA was $2.3 million, the third straight quarter of positive adjusted EBITDA.
The company generated $2.2 million of positive operating cash flow and ended the quarter with $124.5 million in cash, equivalents, marketable securities and restricted cash, with no debt outstanding. Inogen reiterated full-year revenue guidance of $354M–$357M and raised full-year adjusted EBITDA guidance to approximately $2 million. The company also initiated a limited U.S. release of the Simeox airway clearance device.